Drug name - Alunbrig
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Jul, 2030
(7 years from now) | |
| US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(13 years from now) | |
| CN102105150A | TAKEDA PHARMS USA | Phosphorous Derivatives As Kinase Inhibitors |
May, 2029
(6 years from now) | |
| CN102105150B | TAKEDA PHARMS USA | Phosphorous Derivatives As Kinase Inhibitors |
May, 2029
(6 years from now) | |
| CN107108559B | TAKEDA PHARMS USA | 5 - -N4-(2 -) (Dimethyl Phosphoryl) Phenyl] -N2-(2 - -4-(4 - (4 --- Yl)--- Piperazin - -1 - Piperidin - -1 - Yl] - Phenyl) - Pyrimidine - -2, 4 - - Diamine Crystalline Form |
Oct, 2035
(13 years from now) | |
| CN107108559A | TAKEDA PHARMS USA | 5 - -N4-(2 - (- Dimethyl) Phenyl] -N2-(2-Methoxy - -4-[4 - (4-Methylpiperazine - -1 - Yl)--1 - Group]--2, 4-Diamine In Crystalline Form |
Oct, 2035
(13 years from now) | |
| EP2300013A1 | TAKEDA PHARMS USA | Phosphorous Derivatives As Kinase Inhibitors |
May, 2029
(6 years from now) | |
| EP2300013A4 | TAKEDA PHARMS USA | Phosphorous Derivatives As Kinase Inhibitors |
May, 2029
(6 years from now) | |
| EP2300013B1 | TAKEDA PHARMS USA | Phosphorous Derivatives As Kinase Inhibitors |
May, 2029
(6 years from now) | |
| EP3209647B1 | TAKEDA PHARMS USA | Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine |
Oct, 2035
(13 years from now) | |
| EP3209647A1 | TAKEDA PHARMS USA | Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine |
Oct, 2035
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(6 years from now) | |
| US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(11 years from now) | |
Drugs and Companies using BRIGATINIB ingredient
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 30MG | TABLET;ORAL | Prescription |
| 90MG | TABLET;ORAL | Prescription |
| 180MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.